Free Shipping Orders >$250
✓ FREE & Private Global Delivery ›
✓ We Dispatch The Freshest Batch
✓ Discreet Shipping Within 24h Daily
✓ 100% Original Products Guaranteed
✓ Great Customer Service
✓ Competitive prices on all products

Ipca Labs

Ipca Laboratories is an international pharmaceutical company based in Mumbai, India. It produces Theo bromine, Acetylthiophene, and P-Bromo Toluene as Active Pharmaceutical Ingredients (APIs). Ipca sells these APIs and their intermediates world over. It produces more than 150 formulations that include oral liquids, creams, tablets, dry powders, and capsules. The main activities of the company are to produce and market pharmaceuticals and drugs. The various products of the company include formulations, drug intermediates, and active pharmaceutical ingredients.

For more than 60 years, Ipca has been partnering healthcare globally in over 120 countries and in markets as diverse as Africa, Asia, Australia, Europe and the US.

Ipca is a fully-integrated Indian pharmaceutical company manufacturing over 350 formulations and 80 APIs for various therapeutic segments. We are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced right from the basic stage at manufacturing facilities inspected by the world’s most discerning drug regulatory authorities like US-FDA, UK-MHRA, EDQM-Europe, WHO-Geneva and many more.

Our international client roster includes global pharmaceutical giants like AstraZeneca, GlaxoSmithKline, Merck, Roche and Sanofi Aventis; most of whom we have been partnering over the years.

At Ipca, quality assurance is an attitude of seeking sustainable betterment in every aspect of our work. The results show in our financials as well as work ethic. Net income for the financial year ended 31st March 2018 was
Rs. 3258.75 Crores (US$ 505 Mn). Net profit was Rs. 233.11 Crores
(US$ 36 Mn).

What’s more, Ipca was awarded as ‘Among the 100 Best Companies to Work in India 2010’ in a study conducted by Great Place to Work® – India in joint collaboration with The Economic Times.